Australian Clinical Labs Limited

Equities

ACL

AU0000148496

Healthcare Facilities & Services

Market Closed - Australian S.E. 02:10:45 2024-04-26 am EDT 5-day change 1st Jan Change
2.46 AUD -1.20% Intraday chart for Australian Clinical Labs Limited +3.80% -14.88%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Australia shares inch lower as miners weigh; GDP data in focus RE
Australian Clinical Labs Falls 11% After Trimming Interim Dividend on Lower H1 FY24 EPS MT
Transcript : Australian Clinical Labs Limited, H1 2024 Earnings Call, Feb 28, 2024
Australian Clinical Labs Slashes Interim Dividend as Underlying H1 FY24 EPS Falls 49% MT
Australian Clinical Labs Posts H1 FY24 Revenue Down 6.4% to AU$337.3 Million; Underlying Diluted EPS of AU$0.0511 MT
Australian Clinical Labs Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Australian Clinical Labs Gets Regulator Approval to Withdraw Healius Takeover Offer MT
Australian Clinical Labs Limited cancelled the acquisition of Healius Limited from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others. CI
Australian shares end higher on miners, Fed rate pivot RE
US Fed's Dovish Stance Lifts Australian Shares MT
Australian Clinical Labs Intends to Withdraw Proposed Healius Takeover MT
Competition Regulator Denies Australian Clinical Labs’ Proposed Takeover of Healius MT
Australia shares hit over 4-mth high on boost from commodities, banks stocks RE
Australian Clinical Labs to withdraw $1 billion offer for Healius; stocks fall RE
Transcript : Australian Clinical Labs Limited - Shareholder/Analyst Call
Australian Clinical Labs Fulfills Conditions for Healius Takeover MT
Australia Inc roiled by string of cyber attacks since late 2022 RE
Australian Clinical Labs Defers Healius Acquisition EGM MT
Australian Clinical Labs Chairman to Resume Role MT
Australian Clinical Labs Limited canceled the acquisition of Healius Limited CI
Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director CI
Australian Clinical Labs Lowers Final Dividend as Fiscal 2023 Profit Falls; Shares Plunge 14% MT
Transcript : Australian Clinical Labs Limited, 2023 Earnings Call, Aug 22, 2023
Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year 2024 CI
Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023 CI
Chart Australian Clinical Labs Limited
More charts
Australian Clinical Labs Limited is a private provider of pathology services. Its laboratories perform a range of pathology tests each year for a range of clients, including doctors, specialists, patients, hospitals, and corporate clients. It performs a range of services for doctors, patients, and corporate clients, including routine pathology tests, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology and cytopathology, hematology, allergy and immunology, serology and microbiology, infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing. Its specialist services include molecular cancer services, obstetrics and gynecology, pharmacogenetic testing, gastroenterology, and hospital services. It has operations in Victoria, New South Wales, Western Australia, South Australia, Queensland, and the Northern Territory.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.46 AUD
Average target price
3.096 AUD
Spread / Average Target
+25.84%
Consensus
  1. Stock Market
  2. Equities
  3. ACL Stock
  4. News Australian Clinical Labs Limited
  5. Competition Regulator Denies Australian Clinical Labs’ Proposed Takeover of Healius